|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||1.93 - 1.97|
|52 Week Range||1.75 - 3.79|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
NEW YORK, NY / ACCESSWIRE / October 20, 2017 / The Dow Jones and S&P 500 rallied late to close in the green Thursday, which was the 30th anniversary of the 1987 Black Monday stock market crash. The Dow ...
Prana Biotechnology Ltd today announced a research collaboration with Takeda Pharmaceuticals International, Inc. to study the ability of Prana’s investigational movement disorders compound, PBT434, to slow or prevent neurodegeneration of the gastrointestinal system.
Prana Biotechnology Ltd today announced the article “The novel compound PBT434 prevents iron-mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease” was accepted for publication in the peer reviewed journal Acta Neuropathologica Communications.
NEW YORK, NY / ACCESSWIRE / July 5, 2017 / Shares of both Opexa Therapeutics and Prana Biotechnology saw a big trading day on Monday. Opexa shares exploded after traders found out that the company would ...
David Stamler, M.D., has joined Prana Biotechnology as Chief Medical Officer and Senior Vice President, Clinical Development, based in San Francisco. Prior to joining Prana, Dr.